Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.
Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Weintraub D, Sampaio C; the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Seppi K, et al. Among authors: katzenschlager r. Mov Disord. 2019 Feb;34(2):180-198. doi: 10.1002/mds.27602. Epub 2019 Jan 17. Mov Disord. 2019. PMID: 30653247 Free PMC article. Review.
Levodopa in the treatment of Parkinson's disease: current controversies.
Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F. Olanow CW, et al. Among authors: katzenschlager r. Mov Disord. 2004 Sep;19(9):997-1005. doi: 10.1002/mds.20243. Mov Disord. 2004. PMID: 15372588 Review.
Role of LINGO1 polymorphisms in Parkinson's disease.
Haubenberger D, Hotzy C, Pirker W, Katzenschlager R, Brücke T, Zimprich F, Auff E, Zimprich A. Haubenberger D, et al. Among authors: katzenschlager r. Mov Disord. 2009 Dec 15;24(16):2404-7. doi: 10.1002/mds.22768. Mov Disord. 2009. PMID: 19908305 Free PMC article.
Long-term antidyskinetic efficacy of amantadine in Parkinson's disease.
Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, Ott E, Kloiber I, Haubenberger D, Auff E, Poewe W. Wolf E, et al. Among authors: katzenschlager r. Mov Disord. 2010 Jul 30;25(10):1357-63. doi: 10.1002/mds.23034. Mov Disord. 2010. PMID: 20198649 Clinical Trial.
Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study.
Eggert K, Squillacote D, Barone P, Dodel R, Katzenschlager R, Emre M, Lees AJ, Rascol O, Poewe W, Tolosa E, Trenkwalder C, Onofrj M, Stocchi F, Nappi G, Kostic V, Potic J, Ruzicka E, Oertel W; German Competence Network on Parkinson's Disease. Eggert K, et al. Among authors: katzenschlager r. Mov Disord. 2010 May 15;25(7):896-905. doi: 10.1002/mds.22974. Mov Disord. 2010. PMID: 20461807 Clinical Trial.
120 results